Global Preeclampsia Diagnostics Market Research Report - Industry Analysis, Size, Share, Growth, Trends And Forecast 2023 to 2030

Description

List of Tables

The global demand for Preeclampsia Diagnostics Market is presumed to reach the market size of nearly USD 4177.69 MN by 2030 from USD 1373.32 MN in 2022 with a CAGR of 14.92% under the study period 2023 - 2030.

Preeclampsia is a hypertension condition of pregnancy that affects roughly 5% of all pregnant women worldwide, with 0.5 percent to 1% developing severe cases. After 20 weeks of pregnancy, new development of high blood pressure and proteinuria are diagnostic criteria for preeclampsia.

Market Dynamics

The global preeclampsia Diagnostics market is primarily driven by rising preeclampsia incidences. The market for preeclampsia diagnostics is predicted to expand due to the constantly increasing need for its detection and treatment. The demand for early detection of preeclampsia among pregnant women is expected to rise as maternal and perinatal death, and morbidity rates rise. Furthermore, the growing research and development of new tests to detect biomarkers that indicate preeclampsia are likely to promote market growth. Moreover, rising healthcare provider awareness of effective screening tools for the illness, and growing knowledge of the signs and symptoms related to preeclampsia among expecting mothers, are expected to propel the preeclampsia diagnostics market forward at a quick pace.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of preeclampsia diagnostics. The growth and trends of preeclampsia diagnostics industry provide a holistic approach to this study.

Market Segmentation

This section of the preeclampsia diagnostics market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Test Type

Blood Tests
Urine Analysis

By Product Type

Instruments
Consumables

By End-User

Hospitals
Specialty Clinics
Diagnostic Centers
Others

Regional Analysis

This section covers the regional outlook, which accentuates current and future demand for the Preeclampsia Diagnostics market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the preeclampsia diagnostics market include F. Hoffmann-La Roche Ltd., PerkinElmer Inc., DRG INSTRUMENTS GMBH, Thermo Fisher Scientific Inc., Diabetomics, Inc., Metabolomic Diagnostics Ltd., Sera Prognostics, Siemens Healthineers AG, Bayer AG. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

Product Code: VMR11216696

1 . PREFACE

1.1. Report Description
- 1.1.1. Objective
- 1.1.2. Target Audience
- 1.1.3. Unique Selling Proposition (USP) & offerings
1.2. Research Scope
1.3. Research Methodology
- 1.3.1. Market Research Process
- 1.3.2. Market Research Methodology

2 . EXECUTIVE SUMMARY

2.1. Highlights of Market
2.2. Global Market Snapshot

3 . PREECLAMPSIA DIAGNOSTICS - INDUSTRY ANALYSIS

3.1. Introduction - Market Dynamics
3.2. Market Drivers
3.3. Market Restraints
3.4. Opportunities
3.5. Industry Trends
3.6. Porter's Five Force Analysis
3.7. Market Attractiveness Analysis
- 3.7.1 By Test Type
- 3.7.2 By Product Type
- 3.7.3 By End-user
- 3.7.4 By Region

4 . VALUE CHAIN ANALYSIS

4.1. Value Chain Analysis
4.2. Raw Material Analysis
- 4.2.1. List of Raw Materials
- 4.2.2. Raw Material Manufactures List
- 4.2.3. Price Trend of Key Raw Materials
4.3. List of Potential Buyers
4.4. Marketing Channel
- 4.4.1. Direct Marketing
- 4.4.2. Indirect Marketing
- 4.4.3. Marketing Channel Development Trend

5 . IMPACT ANALYSIS OF COVID-19 OUTBREAK

6 . GLOBAL PREECLAMPSIA DIAGNOSTICS MARKET ANALYSIS BY TEST TYPE

6.1 Overview by Test Type
6.2 Historical and Forecast Data
6.3 Analysis by Test Type
6.4 Blood Tests Market by Regions
6.5 Urine Analysis Market by Regions

7 . GLOBAL PREECLAMPSIA DIAGNOSTICS MARKET ANALYSIS BY PRODUCT TYPE

7.1 Overview by Product Type
7.2 Historical and Forecast Data
7.3 Analysis by Product Type
7.4 Instruments Market by Regions
7.5 Consumables Market by Regions

8 . GLOBAL PREECLAMPSIA DIAGNOSTICS MARKET ANALYSIS BY END-USER

8.1 Overview by End-user
8.2 Historical and Forecast Data
8.3 Analysis by End-user
8.4 Hospitals Market by Regions
8.5 Specialty Clinics Market by Regions
8.6 Diagnostic Centers Market by Regions
8.7 Others Market by Regions

9 . GLOBAL PREECLAMPSIA DIAGNOSTICS MARKET ANALYSIS BY GEOGRAPHY

9.1. Regional Outlook
9.2. Introduction
9.3. North America
- 9.3.1. Overview, Historic and Forecast Data
- 9.3.2. North America By Segment
- 9.3.3. North America By Country
- 9.3.4. United State
- 9.3.5. Canada
- 9.3.6. Mexico
9.4. Europe
- 9.4.1. Overview, Historic and Forecast Data
- 9.4.2. Europe by Segment
- 9.4.3. Europe by Country
- 9.4.4. United Kingdom
- 9.4.5. France
- 9.4.6. Germany
- 9.4.7. Italy
- 9.4.8. Russia
- 9.4.9. Rest Of Europe
9.5. Asia Pacific
- 9.5.1. Overview, Historic and Forecast Data
- 9.5.2. Asia Pacific by Segment
- 9.5.3. Asia Pacific by Country
- 9.5.4. China
- 9.5.5. India
- 9.5.6. Japan
- 9.5.7. South Korea
- 9.5.8. Australia
- 9.5.9. Rest Of Asia Pacific
9.6. Latin America
- 9.6.1. Overview, Historic and Forecast Data
- 9.6.2. Latin America by Segment
- 9.6.3. Latin America by Country
- 9.6.4. Brazil
- 9.6.5. Argentina
- 9.6.6. Peru
- 9.6.7. Chile
- 9.6.8. Rest of Latin America
9.7. Middle East & Africa
- 9.7.1. Overview, Historic and Forecast Data
- 9.7.2. Middle East & Africa by Segment
- 9.7.3. Middle East & Africa by Country
- 9.7.4. Saudi Arabia
- 9.7.5. UAE
- 9.7.6. Israel
- 9.7.7. South Africa
- 9.7.8. Rest Of Middle East And Africa

10 . COMPETITIVE LANDSCAPE OF THE PREECLAMPSIA DIAGNOSTICS COMPANIES

10.1. Preeclampsia Diagnostics Market Competition
10.2. Partnership/Collaboration/Agreement
10.3. Merger And Acquisitions
10.4. New Product Launch
10.5. Other Developments

11 . COMPANY PROFILES OF PREECLAMPSIA DIAGNOSTICS INDUSTRY

11.1. Company Share Analysis
11.2. Market Concentration Rate
11.3. F. Hoffmann-La Roche Ltd.
- 11.3.1. Company Overview
- 11.3.2. Financials
- 11.3.3. Products
- 11.3.4. Recent Developments
11.4. PerkinElmer Inc.
- 11.4.1. Company Overview
- 11.4.2. Financials
- 11.4.3. Products
- 11.4.4. Recent Developments
11.5. DRG Instruments GMBH
- 11.5.1. Company Overview
- 11.5.2. Financials
- 11.5.3. Products
- 11.5.4. Recent Developments
11.6. Thermo Fisher Scientific Inc.
- 11.6.1. Company Overview
- 11.6.2. Financials
- 11.6.3. Products
- 11.6.4. Recent Developments
11.7. Diabetomics, Inc.
- 11.7.1. Company Overview
- 11.7.2. Financials
- 11.7.3. Products
- 11.7.4. Recent Developments
11.8. Metabolomic Diagnostics Ltd.
- 11.8.1. Company Overview
- 11.8.2. Financials
- 11.8.3. Products
- 11.8.4. Recent Developments
11.9. Sera Prognostics
- 11.9.1. Company Overview
- 11.9.2. Financials
- 11.9.3. Products
- 11.9.4. Recent Developments
11.10. Siemens Healthineers AG
- 11.10.1. Company Overview
- 11.10.2. Financials
- 11.10.3. Products
- 11.10.4. Recent Developments
11.11. Bayer AG
- 11.11.1. Company Overview
- 11.11.2. Financials
- 11.11.3. Products
- 11.11.4. Recent Developments

Note - in company profiling, financial details and recent development are subject to availability or might not be covered in case of private companies